Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

230,191-230,220 of 319,975

filter-aware
44
The slide uses a small multiples approach to show individual patient responses, then aggregates them into two groups (I and II) to demonstrate differential sensitivity.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
45
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
46
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
47
The slide uses a molecular visualization as a background element to represent the drug target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
48
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
49
The slide uses a human anatomy diagram to map specific cancer types to their locations, providing a visual representation of the addressable market.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
50
Includes a biological pathway diagram and a list of potential cancer indications.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
51
The slide uses a three-column layout to define the target product profile (TPP) for a CDK7 inhibitor.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
52
The slide uses a color-coded heatmap to visualize performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
53
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
54
The slide uses two distinct charts to correlate drug exposure time with physiological toxicity (body weight change).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
55
The chart displays sensitivity across 60+ samples. The right side shows a volcano plot for pathway analysis and a conceptual diagram for combination testing.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
56
The slide uses a waterfall plot for single-agent sensitivity and a heatmap for combination synergy, highlighting specific patient response rates for different mechanisms of action.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
57
Includes a Venn diagram and two line charts showing Log2FoldChange vs concentration.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
58
The slide features a 3D molecular visualization of the protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
59
The chart compares % Reduction PLN Weight across different doses of EXS4318 versus a failed competitor drug.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
60
The slide uses a traffic-light color coding system to highlight the superior profile of EXS4318.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
61
The slide uses a process-flow layout with icons representing each stage.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
62
The background features a 3D molecular visualization, likely representing the LSD1 protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
63
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
64
The slide uses a hub-and-spoke diagram to illustrate the interaction of LSD1 with various protein complexes, receptors, and RNAs.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
65
The slide uses a biological process diagram to explain the mechanism of action for a drug candidate ('539).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
66
The slide uses a process flow diagram to explain the therapeutic mechanism.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
67
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
68
The slide uses a three-column layout to define the technical requirements for a drug candidate.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
69
The table uses a traffic-light color coding system to indicate performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
70
The slide outlines a specific workflow involving generative design, ML, and active learning.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
71
The chart uses a scatter plot to visualize the Pareto front in drug discovery, highlighting the selection of compounds 1 and 2.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
72
The slide uses two distinct chart types (dot plot and line chart with error bars) to illustrate the safety profile of the drug candidate '539.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
73
Data shows heterogeneity of response across different patient samples, categorized by differentiation level.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit